Despite trial delays, incomplete or obtuse data, and refutable and questionable statistics, the CEO and many BOD have been rewarded quite handsomely with cheap stock options.
It probably would have been more prudent to tie the majority of these options grants not to the initiation, but rather the successful completion, of these trials.
Again, this company has been run more like a country club than a pioneering biotechnology company.
The next PR that I expect will be to announce the ASM. I will be quite peeved if it’s not in-person, as I believe this company at least owes its stakeholders the opportunity to meet face-to-face.
News 
Market Data 
Discover 
AI
